Epanova® for Lowering Very High Triglycerides II (EVOLVE II) (EVOLVEII)

• ClinicalTrials.gov Identifier: NCT02009865
• Recruitment Status: Completed
• First Posted: December 12, 2013
• Results First Posted: January 15, 2016
• Last Update Posted: September 10, 2019
• Sponsor: AstraZeneca
• Information provided by (Responsible Party): AstraZeneca

Study Description

Brief Summary:

This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia. The study consists of an approximately 8-week screening period that includes a diet and lifestyle stabilization and washout period and a 12-week treatment period.

Condition or disease	Intervention/treatment	Phase
Hypertriglyceridemia	Drug: Epanova; Drug: Olive Oil	Phase 3

Detailed Description:

[During the screening period and treatment period, all visits are to be within ±3 days of the scheduled time.]

Screening Period:

Visit 1 will occur at Week -8 for subjects requiring washout and/or statin, cholesterol-absorption inhibitor (CAI), or statin-CAI stabilization. This includes subjects who:

• Were previously on omega-3 drugs/supplements;
• Require adjustment to or addition of permitted statins, CAI, or statin-CAI combination;
• Have not been on a permitted stable dose of statin, CAI, or statin-CAI combination for at least 4 weeks prior to Visit 1; and/or
• Need to washout of bile acid sequestrants, fibrates, niacin, and other supplements known to alter lipid metabolism.

For these subjects who require washout and/or statin, CAI, or statin-CAI stabilization, at Visit 1 (Week -8) screening procedures will be performed. Subjects will return at Visit 1a (Week -2) for their first qualifying lipid measurement.

For subjects not requiring washout, Visit 1 will occur at Week -2. All screening procedures will be performed at this visit including the first qualifying lipid measurement.

At Visit 2 (Week -1), all subjects will return for their second lipid qualifying measurement. If at Visit 2 the subject does not have an average TG ≥500 mg/dL (6 mmol/L) and <2500 mg/dL (28 mmol/L), the TG measurement may be repeated one additional time after Visit 2 (Visit 2a). The subject's qualifying measurement would be the average of Visit 1 or 1a + Visit 2 + Visit 2a (repeat measurement).

To be eligible for randomization, the subject must have a qualifying TG ≥500 mg/dL (6 mmol/L) and <2500 mg/dL (28 mmol/L). Of the total number of subjects, approximately 50% will have a qualifying TG >885 mg/dL (10 mmol/L) and <2500 mg/dL (28 mmol/L). Once approximately 50% of the total subjects has been reached for each TG group, enrollment of subjects with that specific TG criterion will stop. Subjects will be equally allocated to each treatment group.

[At the screening visit, all subjects will receive counseling regarding the National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) diet and will receive basic instructions on how to follow this diet. See Appendix C.]

Treatment Period:

At Visit 3 (Week 0), approximately 116 subjects will be randomized in a 1:1 ratio to receive daily olive oil 2 g or Epanova 2 g. Subjects will be stratified by lipid-altering drugs to ensure a balanced allocation of subjects who are users and non-users of the following permitted lipid-altering drugs in each treatment group: statin, CAI, or statin-CAI combination. During the treatment period, subjects will return to the site at Visit 4 (Week 6), Visit 5 (Week 10), and Visit 6 (Week 12) for efficacy and safety evaluations.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 379 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)
• Actual Study Start Date: December 16, 2013
• Actual Primary Completion Date: December 23, 2014
• Actual Study Completion Date: December 23, 2014

Arms and Interventions

Arm	Intervention/treatment
Experimental: Epanova 2 g/day; Arm 1	Drug: Epanova; Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.; Other Name: omega-3 free fatty acids
Placebo Comparator: Olive Oil 2 g/day; Arm 2	Drug: Olive Oil; Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.; Other Name: placebo comparator

Outcome Measures

Primary Outcome Measures :

1. Percent Change in Triglyceride for All Subjects [ Time Frame: From Baseline to Week 12 Endpoint ]
   This primary endpoint was tested in parallel together with the first of the secondary endpoints, each at 0.025 Type I error rate.

Secondary Outcome Measures :

1. Percent Change in Triglycerides for Subjects With at Least 1 Qualifying Triglyceride >885 mg/dL [ Time Frame: From Baseline to Week 12 Endpoint ]
   This first secondary endpoint in subjects with at least 1 qualifying triglyceride >885 mg/dL was tested in parallel together with the primary endpoint, each at 0.025 Type I error rate.
2. Percent Change in Non-High-Density Lipoprotein Cholesterol (mg/dL) [ Time Frame: From Baseline to Week 12 Endpoint ]
   This secondary endpoint, together with the 3rd. and 4th secondary ones, was treated as the core secondary, and the p value from the hypothesis test on its treatment comparison was adjusted by using Hommel's procedure.
3. Percent Change in High-Density Lipoprotein Cholesterol (mg/dL) [ Time Frame: From Baseline to Week 12 Endpoint ]
   This secondary endpoint, together with the 2nd. and 4th. secondary ones, was treated as the core secondary, and the p value from the hypothesis test on its treatment comparison was adjusted by using Hommel's procedure.
4. Percent Change in Triglyceride(mg/dL) in Subjects With Biochemically Defined Fredrickson Type V (Triglyceride/Very-Low-Density Lipoprotein Cholesterol ≥6) [ Time Frame: From Baseline to Week 12 Endpoint ]
   This secondary endpoint in subjects with Biochemically Defined Fredrickson Type V (Triglyceride/Very-Low-Density Lipoprotein Cholesterol ≥6), together with the 2nd. and 3rd.secondary ones, was treated as the core secondary, and the p value from the hypothesis test on its treatment comparison was adjusted by using Hommel's procedure.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 130 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Understanding of the study procedures, willingness to adhere to the study schedule, and agreement to participate in the study by giving written informed consent prior to screening;
2. Willing to use an appropriate and effective method of contraception;
3. Qualifying (average of Visit 1 or 1a + Visit 2 + Visit 2a [repeat measurement]) serum TG ≥500 mg/dL (6 mMol/L) and <2500 mg/dL (28 mMol/L);
4. Body mass index ≥20 kg/m2;
5. Untreated dyslipidemia or dyslipidemia treated with a statin, CAI, or statin-CAI combination that has been stable for 6 weeks prior to randomization; and
6. Willingness to maintain current physical activity level and follow the TLC diet throughout the study.

Exclusion Criteria:

1. Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish;
2. Known lipoprotein lipase impairment;
3. Known non-responder to omega-3 or fenofibrate therapy;
4. Use of any prescription medications containing EPA and/or DHA (eg, Lovaza® or Vascepa®) within 8 weeks prior to randomization. Up to 1 g capsule/day of an omega-3 dietary supplement will be permitted;
5. Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins <200 mg), or any supplement used to alter lipid metabolism including but not limited to dietary fiber supplements, red rice yeast supplements, garlic supplements, soy isoflavone supplements, sterol/stanol products, or policosanols at screening;
6. Use of tamoxifen, estrogens, or progestins that has not been stable for >4 weeks at screening or is unstable prior to randomization;
7. Use of oral or injected corticosteroids or anabolic steroids prior to randomization;
8. History of hospitalization for pancreatitis in the last 5 years;
9. Uncontrolled diabetes (hemoglobin A1c [HbA1c] >10%);
10. Uncontrolled hypothyroidism or thyroid-stimulating hormone (TSH) >5 mIU/L;
11. History of cancer (other than basal cell carcinoma) in the past 2 years;
12. Cardiovascular event (ie, myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient heart attack, unstable congestive heart failure requiring a change in treatment), revascularization procedure or vascular surgery within 6 months of randomization;
13. Use of simvastatin 80 mg or Vytorin 10/80 mg;
14. Recent history (within 6 months of randomization) of significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal, or immunologic disease;
15. Poorly controlled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg);
16. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × the upper limit of normal (ULN); if ALT/AST is >3 × ULN, the levels have been stable for 3 months and are <5 × ULN;
17. Exposure to any investigational product within 4 weeks of randomization; or
18. Any condition or therapy which, in the opinion of the Investigator, might pose a risk to the subject or make participation in the study not in the subject's best interest.

Contacts and Locations

Locations

United States, California

Research Site

Los Angeles, California, United States, 90057

United States, Florida

Research Site

Saint Petersburg, Florida, United States, 33709

United States, Illinois

Research Site

Addison, Illinois, United States, 60101

United States, Kentucky

Research Site

Louisville, Kentucky, United States, 40213

United States, Ohio

Research Site

Cincinnati, Ohio, United States, 45227

Research Site

Cincinnati, Ohio, United States, 45246

Research Site

Columbus, Ohio, United States, 43213

Research Site

Kettering, Ohio, United States, 45429

Research Site

Lyndhurst, Ohio, United States, 44124

United States, Oklahoma

Research Site

Oklahoma City, Oklahoma, United States, 73103

United States, Pennsylvania

Research Site

Philadelphia, Pennsylvania, United States, 19104

United States, South Carolina

Research Site

Orangeburg, South Carolina, United States, 29118

United States, Tennessee

Research Site

Bristol, Tennessee, United States, 37620

United States, Texas

Research Site

Houston, Texas, United States, 77074

Research Site

Katy, Texas, United States, 77450

Canada, Quebec

Research Site

Chicoutimi, Quebec, Canada, G7H 7K9

Czechia

Research Site

Hradec Kralova, Czechia, 50005

Research Site

Trutnov, Czechia, 541 21

Research Site

Zlín, Czechia, 76275

Denmark

Research Site

Esbjerg, Denmark, 6700

Research Site

Gentofte, Denmark, 2820

Research Site

Herlev, Denmark, 2730

Research Site

Viborg, Denmark, 8800

Hungary

Research Site

Baja, Hungary, 6500

Research Site

Balatonfured, Hungary, 8230

Research Site

Budapest, Hungary, 1062

Research Site

Debrecen, Hungary, 4031

Research Site

Debrecen, Hungary, 4032

Research Site

Szikszó, Hungary, 3800

Research Site

Székesfehérvár, Hungary, 8000

Research Site

Sátoraljaújhely, Hungary, 3980

Netherlands

Research Site

Alkmaar, Netherlands, 1815JD

Research Site

Amsterdam, Netherlands, 1105 AZ

Russian Federation

Research Site

Barnaul, Russian Federation, 656055

Research Site

Ekaterinburg, Russian Federation, 620219

Research Site

Kemerovo, Russian Federation, 650002

Research Site

Moscow, Russian Federation, 121551

Research Site

Moscow, Russian Federation, 121552

Research Site

Saint Petersburg, Russian Federation, 196601

Research Site

Tomsk, Russian Federation, 634012

Sponsors and Collaborators

AstraZeneca

More Information

• Responsible Party: AstraZeneca
• ClinicalTrials.gov Identifier: NCT02009865
• Other Study ID Numbers: D5880C00001; OM-EPA-011 ( Other Identifier: AstraZeneca Plc )
• First Posted: December 12, 2013
• Results First Posted: January 15, 2016
• Last Update Posted: September 10, 2019
• Last Verified: August 2019

Keywords provided by AstraZeneca:

Hypertriglyceridemia; Dyslipidemia; Eicosapentaenoic acid; EPA; Docosahexaenoic acid; DHA

Additional relevant MeSH terms:

Hypertriglyceridemia; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases